View From The Med Week 24 Now Available

It’s been an enlightening week, not least because we’ve been contrasting the European regulatory set up with that employed by FDA. As European parliaments and commissions discuss what happens next, we’re a bit worried that they may overshoot in certain areas, but on the whole they seem to be on the money… speaking of which, the one fly in the ointment is that nobody’s really talking about the cost of this new infrastructure.

Anyway, read all about it on this week’s View From The Med, which can be found here.